CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...

WILMINGTON, NC (WWAY) — Novant Health New Hanover Regional Medical Center is offering the Barostim implant for heart failure patients. The first local recipient, Chuck Moon, says the results have been ...

CVRx announced today the launch of its second-generation programmer that is compatible with all Barostim implantable systems. FDA approved the new programmer in April. The Minneapolis, MN-based ...

CVRx Inc (NASDAQ:CVRX) announced that the Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of ...

Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...

CVRx, Inc. (NASDAQ: CVRX) on Thursday initiated the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim in a ...

CVRx shares were 19% higher, at $8.48, after the company said that the Centers for Medicare and Medicaid Services has proposed keeping CVRx's Barostim implant procedure as part of the New Technology ...

Please provide your email address to receive an email when new articles are posted on . CVRx announced it has launched a next-generation version of its ...

CVRx (CVRX) shares bounced back from a post-earnings slump on Thursday after the MedTech firm announced that health insurer Humana (HUM) has issued a Medicare Advantage coverage policy for its ...

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc (CVRX). (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has ...